SlideShare a Scribd company logo
Marsa Corporate Finance GmbH, Basel Switzerland
Financing of Early-stage Companies
Strictly private andconfidential
April 2019
An Overview of Funding Facilities
to baselarea.swiss DayOne Accelerator, 30.04.2019
1 Introduction and Investment Thoughts
2 Development Stage of Companies
3 Life Cycle
4 Financing Means
4.1 Equity
4.2 Equity Investor Types
4.3 Loans
4.4 Loan Characteristics
4.5 Non-dilutive Funding
5 Investment Size and Expected Returns - IRR
6 Business Case Presentation
7 Contact
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
2
Contents
Introduction to Fund Raising for Early-stage
Companies
Valuation of early-stage companies Marsa Corporate Finance
GmbH
April 2019
3
1 Introduction and Investment Thoughts
Your Fund Raising Strategy should based on important parameters, such as
• which round of financing is it?
• which development phases is your startup/project in?
• which is the investment size?
• which future funds will the company/project need and when?
• which type of funds should be applied for (Equity, non-Equity)?
• which types of investors are best to approach?
• which is the company’s offer to investors?
Introduction
1 Introduction & InvestmentThoughts
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
4
Development stage of young companies
2 Early Stage Companies Role in theEconomy
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
5
Revenues
Business/Product
Idea
No revenues,
Operatinglosses
Start-up companies
No or small revenues,
Increasing losses
2nd stage companies
Growing revenues
move towardsprofits
Losses/earnings
~ 8-14 20 YEARS
RESEARCH & DEVELOPMENT PHASE RETURN PHASE EXPIRY
REGISTRATION
PHASEIII
PHASEII
PHASEI
PRE-CLINICALSAFETY DOSE EFFICACY / APPROVAL
“STAR” “CASH COW” “DOG”~10
%
10 -45% 40 - 65% ~80%
BREAKEVE
N
ß RISK-ADJUSTED DISCOUNTED CASH FLOW à
Chance of
SUCCESS
<5%
ANIMALS ~10s ~ 100s ~ 100s – 1,000s
PTS
COSTS
SALESp<0.05
P/E >20x P/E ~10-15x P/E > 6-10x
“MATURE”
P/E ~ 15x
0
LIFE CYCLE BIOTECHNOLOGY COMPANIES
00
Life cycle of young companies, e.g. Pharmaceutical
2 Early Stage Companies Role in theEconomy
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
6
Valuation Methods DCF, rNPV Multiples, Peer groups, other
Paid in at inception of the startup company by the founders:
◦ In GmbH CHF 20k
◦ In AG CHF 100k
◦ From founder shareholders
◦ Possible is some in-kind or partial pay-in (e.g. 50% = «Teil-Liberierung»)
◦ Rapidly consumed
Equity - Initial Share Capital
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
7
4 Financing Means
Early Stage: (50k – 500k)
• FFF – pure money
• Seed Investors, some early-stage VC
• Business Angels – often with some «soft money» as contacts and support
Expansion Phase
• Venture Capital Investors
Late Stage
• Venture Capital Investors
• Private Equity Investors
Other types
• Crowd Funding
• Corporate Ventures
• Family Offices
Equity – Investors
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
8
4 Financing Means
Loans may come in various constructs with rather different implications and at different stages
• Straight loans e.g. from banks or private investors (rather in a later stage)
• Convertible loans (rather early, e.g. if no meaningful valuation is possible)
• Option Debentures (rather unusual in early stage startups)
• Warrants
• ....
Loans
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
9
4 Financing Means
Straight loans
• Interest baring or without interest
• Liabilities in balance sheet
• Subordination possible to cure
Convertible loans
• Compare to straight loans, however can be converted into equity
• Subordination possible to cure
• «switch side» on balance sheet in case of over-indebtedness
• Conversion triggers are important
• Who holds right to convert and when?
Loan Characteristics
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
10
4 Financing Means
Option debentures
• Special form of convertible, not very common
• type of debt instrument unsecured by collateral, hence rely on the creditworthiness and
reputation of the issuer for support.
• may pay periodic interest payments
Warrants
• do not represent actual ownership in the stock
• holder has the right to buy stock from the company at a specified price within
a designated time period
• Dilution,because the exercise of a warrant will increase a company's outstanding shares
Loan Characteristics
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
11
4 Financing Means
• Governmental or supra-national grants
EU, Innosuisse,
• Foundations offer project funding or individuals’ support
Gebert Ruef, Hasler, etc. ....
• Donations
• Patient organisations
• Refunds or reductions of Development Cost (EMA), Orphan, etc., .....
Non-dilutive Funding
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
12
4 Financing Means
Typical Investment Size – IRR Expectations
5 Investment Size and Expected Returns - IRR
Investor Total Investment Size IRR
Business Angel CHF 10k + n.a.
FFF n.a. n.a.
Early-stage VC CHF 0.5 -5.0m > 10%
Late-stage VC CHF 5m + > 10%
Private Equity CHF xxm > 12-16%
Non-dilutive variable n.a.
The internal rate of return (IRR) is the discount
rate providing a net value of zero for a future
series of cash flows.
IRR and net present value (NPV) are used when
selecting investments based on their returns.
The main difference between IRR and NPV is
that NPV is an actual amount while the IRR is
the interest yield as a percentage expected
from an investment.
Investors Expectations – ROI - Return
Return in investment is the difference between Profits minus Cost in relation to Cost
or:
Example: Investor puts 50 € and yields at end of investment 70 €; Return = 40 %:
Earnings – Cost Earnings
Return = ---------------------- = -------------- -1
Cost Cost
Profit
Return = --------------------------
Invested Capital
70 – 50 20
Return = -------------- = ------- = 40%
50 50
5 Investment Size and Expected Returns - IRR
IRR
Calculating IRR
A company is deciding whether to purchase new equipment that costs $500,000.
Life of the new asset to be 4 years
generate an additional $160,000 of annual profits.
In the 5. year, the company plans to sell the equipment for its salvage value of $50,000.
Meanwhile, another similar investment option can generate a 10% return. This is higher than
the company’s current hurdle rate of 8%. The goal is to make sure the company is making
better use of its cash.
To make a decision, the IRR for investing in the new equipment is calculated below.
IRR of 13%, using the Excel function, =IRR(). From a financial standpoint, the company should
make the purchase, because the IRR is both greater than the hurdle rate and the IRR for the
alternative investment.
5 Investment Size and Expected Returns - IRR
Find IRR and NPV functions as preset functions in MS Excel
Business Case Presentation
Fund Raising Document Set consists of
• Pitch Deck
• Business Plan incl. Financial Plan (3+ years) PnL, CF, BS
• IP Situtation and Strategy
• Use of Funds – incl. Scenarios
• Next Financing Needs (Timing, Size)
• Supplement Documents
Important Aspects
• Consistency of all documents and messages
• Be reliable and deliver
• Communicate important events in timely manner – no surprises
6 Investment Size and Expected Returns - IRR
Thank you - Your contact at Marsa Corporate Finance GmbH
7 Contact
Andreas J. Schulze, CEO
Marsa Corporate Finance GmbH
4010 Basel
www.marsaco.com
+41 76 341 18 76
andreas.schulze@marsaco.com
Financing of early-stage companies Marsa Corporate Finance GmbH April 2019
17

More Related Content

What's hot

Startup Finances
Startup FinancesStartup Finances
Startup Finances
Laura Faulconer
 
How to Finance a Start-Up
How to Finance a Start-UpHow to Finance a Start-Up
How to Finance a Start-Up
Illinois workNet
 
Joseph Fabiilli | What Venture Capitalists Expect
Joseph Fabiilli | What Venture Capitalists ExpectJoseph Fabiilli | What Venture Capitalists Expect
Joseph Fabiilli | What Venture Capitalists Expect
Joseph Fabiilli
 
Different Startup Funding Stages : How Funding Works
Different Startup Funding Stages : How Funding WorksDifferent Startup Funding Stages : How Funding Works
Different Startup Funding Stages : How Funding Works
myHQ
 
Introduction to entrepreneurial finance
Introduction to entrepreneurial financeIntroduction to entrepreneurial finance
Introduction to entrepreneurial finance
Anubha Rastogi
 
Careers In Finance 2007 10 04 Draft
Careers In Finance 2007 10 04 DraftCareers In Finance 2007 10 04 Draft
Careers In Finance 2007 10 04 Draft
FNian
 
Types and sources of financing for start up businesses
Types and sources of financing for start up businessesTypes and sources of financing for start up businesses
Types and sources of financing for start up businesses
Harinadh Karimikonda
 
Is your business funding ready
Is your business funding readyIs your business funding ready
Is your business funding ready
Anjana Vivek
 
From Bootstrapping to Venture Rounds: A Startup Case Study
From Bootstrapping to Venture Rounds: A Startup Case StudyFrom Bootstrapping to Venture Rounds: A Startup Case Study
From Bootstrapping to Venture Rounds: A Startup Case Study
Roger Ehrenberg
 
Preparing A B Plan For Equity Investment
Preparing A B Plan For Equity InvestmentPreparing A B Plan For Equity Investment
Preparing A B Plan For Equity Investment
Anjana Vivek
 
WORKING WITH BANKERS AND PRIVATE INVESTORS TO FUND YOUR BUYOUT
WORKING WITH BANKERS AND PRIVATE INVESTORS TO FUND YOUR BUYOUTWORKING WITH BANKERS AND PRIVATE INVESTORS TO FUND YOUR BUYOUT
WORKING WITH BANKERS AND PRIVATE INVESTORS TO FUND YOUR BUYOUT
Kris Geysels
 
I Want / Need Funding
I Want / Need FundingI Want / Need Funding
I Want / Need Funding
Anjana Vivek
 
Finance for Start-ups
Finance for Start-upsFinance for Start-ups
Finance for Start-ups
Anjana Vivek
 
Advantages and disadvantages of venture capital
Advantages and disadvantages of venture capitalAdvantages and disadvantages of venture capital
Advantages and disadvantages of venture capital
jim
 
Financing your new venture
Financing your new ventureFinancing your new venture
Financing your new venture
uottawaehub
 
Proprietorship, Private Ltd. LLP or Partnership..??
Proprietorship, Private Ltd.  LLP or Partnership..?? Proprietorship, Private Ltd.  LLP or Partnership..??
Proprietorship, Private Ltd. LLP or Partnership..??
Anjana Vivek
 
Access to Capital
Access to CapitalAccess to Capital
Access to Capital
GeorgiaPinner
 
Co founder conflicts & challenges
Co founder conflicts & challengesCo founder conflicts & challenges
Co founder conflicts & challenges
Anjana Vivek
 
Start Up Finance
Start Up FinanceStart Up Finance
Start Up FinanceGina Evans
 

What's hot (20)

Startup Finances
Startup FinancesStartup Finances
Startup Finances
 
How to Finance a Start-Up
How to Finance a Start-UpHow to Finance a Start-Up
How to Finance a Start-Up
 
Joseph Fabiilli | What Venture Capitalists Expect
Joseph Fabiilli | What Venture Capitalists ExpectJoseph Fabiilli | What Venture Capitalists Expect
Joseph Fabiilli | What Venture Capitalists Expect
 
Different Startup Funding Stages : How Funding Works
Different Startup Funding Stages : How Funding WorksDifferent Startup Funding Stages : How Funding Works
Different Startup Funding Stages : How Funding Works
 
Introduction to entrepreneurial finance
Introduction to entrepreneurial financeIntroduction to entrepreneurial finance
Introduction to entrepreneurial finance
 
Careers In Finance 2007 10 04 Draft
Careers In Finance 2007 10 04 DraftCareers In Finance 2007 10 04 Draft
Careers In Finance 2007 10 04 Draft
 
Types and sources of financing for start up businesses
Types and sources of financing for start up businessesTypes and sources of financing for start up businesses
Types and sources of financing for start up businesses
 
Business Plan
Business PlanBusiness Plan
Business Plan
 
Is your business funding ready
Is your business funding readyIs your business funding ready
Is your business funding ready
 
From Bootstrapping to Venture Rounds: A Startup Case Study
From Bootstrapping to Venture Rounds: A Startup Case StudyFrom Bootstrapping to Venture Rounds: A Startup Case Study
From Bootstrapping to Venture Rounds: A Startup Case Study
 
Preparing A B Plan For Equity Investment
Preparing A B Plan For Equity InvestmentPreparing A B Plan For Equity Investment
Preparing A B Plan For Equity Investment
 
WORKING WITH BANKERS AND PRIVATE INVESTORS TO FUND YOUR BUYOUT
WORKING WITH BANKERS AND PRIVATE INVESTORS TO FUND YOUR BUYOUTWORKING WITH BANKERS AND PRIVATE INVESTORS TO FUND YOUR BUYOUT
WORKING WITH BANKERS AND PRIVATE INVESTORS TO FUND YOUR BUYOUT
 
I Want / Need Funding
I Want / Need FundingI Want / Need Funding
I Want / Need Funding
 
Finance for Start-ups
Finance for Start-upsFinance for Start-ups
Finance for Start-ups
 
Advantages and disadvantages of venture capital
Advantages and disadvantages of venture capitalAdvantages and disadvantages of venture capital
Advantages and disadvantages of venture capital
 
Financing your new venture
Financing your new ventureFinancing your new venture
Financing your new venture
 
Proprietorship, Private Ltd. LLP or Partnership..??
Proprietorship, Private Ltd.  LLP or Partnership..?? Proprietorship, Private Ltd.  LLP or Partnership..??
Proprietorship, Private Ltd. LLP or Partnership..??
 
Access to Capital
Access to CapitalAccess to Capital
Access to Capital
 
Co founder conflicts & challenges
Co founder conflicts & challengesCo founder conflicts & challenges
Co founder conflicts & challenges
 
Start Up Finance
Start Up FinanceStart Up Finance
Start Up Finance
 

Similar to Funding of early stage companies

Financing Your Business.ruygfrdfyuytgigr
Financing Your Business.ruygfrdfyuytgigrFinancing Your Business.ruygfrdfyuytgigr
Financing Your Business.ruygfrdfyuytgigr
johnoficial420
 
Oct15132654
Oct15132654Oct15132654
Oct15132654
Aritra Biswas
 
Keith quicksilver funding - financing your business
Keith quicksilver funding - financing your businessKeith quicksilver funding - financing your business
Keith quicksilver funding - financing your business
keith quicksilver funding
 
VITALISE Bootcamp - Investment Basics.pdf
VITALISE Bootcamp - Investment Basics.pdfVITALISE Bootcamp - Investment Basics.pdf
VITALISE Bootcamp - Investment Basics.pdf
VITALISEProject
 
CHAPTER-V-FINANCIAL-PLAN and the business.pptx
CHAPTER-V-FINANCIAL-PLAN and the business.pptxCHAPTER-V-FINANCIAL-PLAN and the business.pptx
CHAPTER-V-FINANCIAL-PLAN and the business.pptx
JCLara3
 
Entrepreneur Finance for MBA in Finance
Entrepreneur Finance for MBA in  FinanceEntrepreneur Finance for MBA in  Finance
Entrepreneur Finance for MBA in Finance
RitikMishra68
 
Practical entrepreneurship training part 4 Financing the business
Practical entrepreneurship training part 4 Financing the businessPractical entrepreneurship training part 4 Financing the business
Practical entrepreneurship training part 4 Financing the business
kieranm01
 
Venture capital
Venture capitalVenture capital
Venture capital
Samraiz Tejani
 
Start ups challenges for funding options
Start ups challenges for funding optionsStart ups challenges for funding options
Start ups challenges for funding options
Anjana Vivek
 
NCV 4 New Venture Creation Hands-On Support Slide Show - Module 2
NCV 4 New Venture Creation Hands-On Support Slide Show - Module 2NCV 4 New Venture Creation Hands-On Support Slide Show - Module 2
NCV 4 New Venture Creation Hands-On Support Slide Show - Module 2
Future Managers
 
MEFA UNIT-IV.doc
MEFA UNIT-IV.docMEFA UNIT-IV.doc
MEFA UNIT-IV.doc
GANDLAGOWTHAMI
 
Venture capital
Venture capitalVenture capital
Venture capital
ponmani thavamani
 
Cf presentation ok
Cf presentation ok Cf presentation ok
Cf presentation ok Muhammad Ali
 
Emerging sources of finance
Emerging sources of finance Emerging sources of finance
Emerging sources of finance
Shivani Desai
 
Introduction to corporate finance
Introduction to corporate financeIntroduction to corporate finance
Introduction to corporate finance
shitalupadhyay
 
Venture Capital: An Entrepreneur's Manual
Venture Capital: An Entrepreneur's ManualVenture Capital: An Entrepreneur's Manual
Venture Capital: An Entrepreneur's ManualBen Holmes
 
Levee de fonds_entrepreneur
Levee de fonds_entrepreneurLevee de fonds_entrepreneur
Levee de fonds_entrepreneuryorickvidal
 
Presentation of training project
Presentation of training projectPresentation of training project
Presentation of training projectsupriyanayyar
 
Investment portfolio ppt
Investment portfolio pptInvestment portfolio ppt
Investment portfolio pptsupriyanayyar
 

Similar to Funding of early stage companies (20)

Financing Your Business.ruygfrdfyuytgigr
Financing Your Business.ruygfrdfyuytgigrFinancing Your Business.ruygfrdfyuytgigr
Financing Your Business.ruygfrdfyuytgigr
 
Oct15132654
Oct15132654Oct15132654
Oct15132654
 
Keith quicksilver funding - financing your business
Keith quicksilver funding - financing your businessKeith quicksilver funding - financing your business
Keith quicksilver funding - financing your business
 
VITALISE Bootcamp - Investment Basics.pdf
VITALISE Bootcamp - Investment Basics.pdfVITALISE Bootcamp - Investment Basics.pdf
VITALISE Bootcamp - Investment Basics.pdf
 
CHAPTER-V-FINANCIAL-PLAN and the business.pptx
CHAPTER-V-FINANCIAL-PLAN and the business.pptxCHAPTER-V-FINANCIAL-PLAN and the business.pptx
CHAPTER-V-FINANCIAL-PLAN and the business.pptx
 
Entrepreneur Finance for MBA in Finance
Entrepreneur Finance for MBA in  FinanceEntrepreneur Finance for MBA in  Finance
Entrepreneur Finance for MBA in Finance
 
Practical entrepreneurship training part 4 Financing the business
Practical entrepreneurship training part 4 Financing the businessPractical entrepreneurship training part 4 Financing the business
Practical entrepreneurship training part 4 Financing the business
 
Venture capital
Venture capitalVenture capital
Venture capital
 
Venture capital
Venture capitalVenture capital
Venture capital
 
Start ups challenges for funding options
Start ups challenges for funding optionsStart ups challenges for funding options
Start ups challenges for funding options
 
NCV 4 New Venture Creation Hands-On Support Slide Show - Module 2
NCV 4 New Venture Creation Hands-On Support Slide Show - Module 2NCV 4 New Venture Creation Hands-On Support Slide Show - Module 2
NCV 4 New Venture Creation Hands-On Support Slide Show - Module 2
 
MEFA UNIT-IV.doc
MEFA UNIT-IV.docMEFA UNIT-IV.doc
MEFA UNIT-IV.doc
 
Venture capital
Venture capitalVenture capital
Venture capital
 
Cf presentation ok
Cf presentation ok Cf presentation ok
Cf presentation ok
 
Emerging sources of finance
Emerging sources of finance Emerging sources of finance
Emerging sources of finance
 
Introduction to corporate finance
Introduction to corporate financeIntroduction to corporate finance
Introduction to corporate finance
 
Venture Capital: An Entrepreneur's Manual
Venture Capital: An Entrepreneur's ManualVenture Capital: An Entrepreneur's Manual
Venture Capital: An Entrepreneur's Manual
 
Levee de fonds_entrepreneur
Levee de fonds_entrepreneurLevee de fonds_entrepreneur
Levee de fonds_entrepreneur
 
Presentation of training project
Presentation of training projectPresentation of training project
Presentation of training project
 
Investment portfolio ppt
Investment portfolio pptInvestment portfolio ppt
Investment portfolio ppt
 

More from DayOne

Understanding the health data future - Deloitte Healthconnect, co-hosted by D...
Understanding the health data future - Deloitte Healthconnect, co-hosted by D...Understanding the health data future - Deloitte Healthconnect, co-hosted by D...
Understanding the health data future - Deloitte Healthconnect, co-hosted by D...
DayOne
 
DayOne Expert Event - Smart Prevention (2020)
DayOne Expert Event - Smart Prevention (2020)DayOne Expert Event - Smart Prevention (2020)
DayOne Expert Event - Smart Prevention (2020)
DayOne
 
5th Annual DayOne Conference (Nov. 2020)
5th Annual DayOne Conference (Nov. 2020)5th Annual DayOne Conference (Nov. 2020)
5th Annual DayOne Conference (Nov. 2020)
DayOne
 
Breathe - Empowering parents of children with asthma
Breathe - Empowering parents of children with asthmaBreathe - Empowering parents of children with asthma
Breathe - Empowering parents of children with asthma
DayOne
 
Pioneering value & data driven healthcare for Patients
Pioneering value & data driven healthcare for PatientsPioneering value & data driven healthcare for Patients
Pioneering value & data driven healthcare for Patients
DayOne
 
Legal Framework for Digital Health Innovation - Data Protection and Security
Legal Framework for Digital Health Innovation - Data Protection and SecurityLegal Framework for Digital Health Innovation - Data Protection and Security
Legal Framework for Digital Health Innovation - Data Protection and Security
DayOne
 
EU regulatory frameworks - Legal challenges and opportunities for digital hea...
EU regulatory frameworks - Legal challenges and opportunities for digital hea...EU regulatory frameworks - Legal challenges and opportunities for digital hea...
EU regulatory frameworks - Legal challenges and opportunities for digital hea...
DayOne
 
Legal framework for digital health innvoation - Protection through patents, d...
Legal framework for digital health innvoation - Protection through patents, d...Legal framework for digital health innvoation - Protection through patents, d...
Legal framework for digital health innvoation - Protection through patents, d...
DayOne
 
Expert Event Legal challenges and opportunities for digital health innovation
Expert Event Legal challenges and opportunities for digital health innovationExpert Event Legal challenges and opportunities for digital health innovation
Expert Event Legal challenges and opportunities for digital health innovation
DayOne
 
Future of aging day one 20200630 zaynakhayat
Future of aging day one 20200630 zaynakhayatFuture of aging day one 20200630 zaynakhayat
Future of aging day one 20200630 zaynakhayat
DayOne
 
Value-based Healthcare - Towards a systems approach in chronic diseasesn
Value-based Healthcare - Towards a systems approach in chronic diseasesnValue-based Healthcare - Towards a systems approach in chronic diseasesn
Value-based Healthcare - Towards a systems approach in chronic diseasesn
DayOne
 
Value-based Healthcare by Lyfegen on Pioneering value & data-driven healthcare
Value-based Healthcare by Lyfegen on Pioneering value & data-driven healthcareValue-based Healthcare by Lyfegen on Pioneering value & data-driven healthcare
Value-based Healthcare by Lyfegen on Pioneering value & data-driven healthcare
DayOne
 
Value-based Healthcare today and tomorrow by Deloitte.
Value-based Healthcare today and tomorrow by Deloitte.Value-based Healthcare today and tomorrow by Deloitte.
Value-based Healthcare today and tomorrow by Deloitte.
DayOne
 
DayOne Experts - Value Based Healthcare
DayOne Experts - Value Based HealthcareDayOne Experts - Value Based Healthcare
DayOne Experts - Value Based Healthcare
DayOne
 
Aging Well project - Workshop 1 mobility
Aging Well project - Workshop 1 mobilityAging Well project - Workshop 1 mobility
Aging Well project - Workshop 1 mobility
DayOne
 
Expert Event DayOneBasel on Mental Health
Expert Event DayOneBasel on Mental HealthExpert Event DayOneBasel on Mental Health
Expert Event DayOneBasel on Mental Health
DayOne
 
20191203 DOE Data Driven Healthcare- Expert Event
20191203 DOE Data Driven Healthcare- Expert Event20191203 DOE Data Driven Healthcare- Expert Event
20191203 DOE Data Driven Healthcare- Expert Event
DayOne
 
Healthcare delivery in the periphery workshop output
Healthcare delivery in the periphery workshop outputHealthcare delivery in the periphery workshop output
Healthcare delivery in the periphery workshop output
DayOne
 
2019.10.30 DayOne Expert Event patient centricity
2019.10.30 DayOne Expert Event patient centricity2019.10.30 DayOne Expert Event patient centricity
2019.10.30 DayOne Expert Event patient centricity
DayOne
 
DayOne Accelerator 2019/20 shortlisted projects
DayOne Accelerator 2019/20 shortlisted projectsDayOne Accelerator 2019/20 shortlisted projects
DayOne Accelerator 2019/20 shortlisted projects
DayOne
 

More from DayOne (20)

Understanding the health data future - Deloitte Healthconnect, co-hosted by D...
Understanding the health data future - Deloitte Healthconnect, co-hosted by D...Understanding the health data future - Deloitte Healthconnect, co-hosted by D...
Understanding the health data future - Deloitte Healthconnect, co-hosted by D...
 
DayOne Expert Event - Smart Prevention (2020)
DayOne Expert Event - Smart Prevention (2020)DayOne Expert Event - Smart Prevention (2020)
DayOne Expert Event - Smart Prevention (2020)
 
5th Annual DayOne Conference (Nov. 2020)
5th Annual DayOne Conference (Nov. 2020)5th Annual DayOne Conference (Nov. 2020)
5th Annual DayOne Conference (Nov. 2020)
 
Breathe - Empowering parents of children with asthma
Breathe - Empowering parents of children with asthmaBreathe - Empowering parents of children with asthma
Breathe - Empowering parents of children with asthma
 
Pioneering value & data driven healthcare for Patients
Pioneering value & data driven healthcare for PatientsPioneering value & data driven healthcare for Patients
Pioneering value & data driven healthcare for Patients
 
Legal Framework for Digital Health Innovation - Data Protection and Security
Legal Framework for Digital Health Innovation - Data Protection and SecurityLegal Framework for Digital Health Innovation - Data Protection and Security
Legal Framework for Digital Health Innovation - Data Protection and Security
 
EU regulatory frameworks - Legal challenges and opportunities for digital hea...
EU regulatory frameworks - Legal challenges and opportunities for digital hea...EU regulatory frameworks - Legal challenges and opportunities for digital hea...
EU regulatory frameworks - Legal challenges and opportunities for digital hea...
 
Legal framework for digital health innvoation - Protection through patents, d...
Legal framework for digital health innvoation - Protection through patents, d...Legal framework for digital health innvoation - Protection through patents, d...
Legal framework for digital health innvoation - Protection through patents, d...
 
Expert Event Legal challenges and opportunities for digital health innovation
Expert Event Legal challenges and opportunities for digital health innovationExpert Event Legal challenges and opportunities for digital health innovation
Expert Event Legal challenges and opportunities for digital health innovation
 
Future of aging day one 20200630 zaynakhayat
Future of aging day one 20200630 zaynakhayatFuture of aging day one 20200630 zaynakhayat
Future of aging day one 20200630 zaynakhayat
 
Value-based Healthcare - Towards a systems approach in chronic diseasesn
Value-based Healthcare - Towards a systems approach in chronic diseasesnValue-based Healthcare - Towards a systems approach in chronic diseasesn
Value-based Healthcare - Towards a systems approach in chronic diseasesn
 
Value-based Healthcare by Lyfegen on Pioneering value & data-driven healthcare
Value-based Healthcare by Lyfegen on Pioneering value & data-driven healthcareValue-based Healthcare by Lyfegen on Pioneering value & data-driven healthcare
Value-based Healthcare by Lyfegen on Pioneering value & data-driven healthcare
 
Value-based Healthcare today and tomorrow by Deloitte.
Value-based Healthcare today and tomorrow by Deloitte.Value-based Healthcare today and tomorrow by Deloitte.
Value-based Healthcare today and tomorrow by Deloitte.
 
DayOne Experts - Value Based Healthcare
DayOne Experts - Value Based HealthcareDayOne Experts - Value Based Healthcare
DayOne Experts - Value Based Healthcare
 
Aging Well project - Workshop 1 mobility
Aging Well project - Workshop 1 mobilityAging Well project - Workshop 1 mobility
Aging Well project - Workshop 1 mobility
 
Expert Event DayOneBasel on Mental Health
Expert Event DayOneBasel on Mental HealthExpert Event DayOneBasel on Mental Health
Expert Event DayOneBasel on Mental Health
 
20191203 DOE Data Driven Healthcare- Expert Event
20191203 DOE Data Driven Healthcare- Expert Event20191203 DOE Data Driven Healthcare- Expert Event
20191203 DOE Data Driven Healthcare- Expert Event
 
Healthcare delivery in the periphery workshop output
Healthcare delivery in the periphery workshop outputHealthcare delivery in the periphery workshop output
Healthcare delivery in the periphery workshop output
 
2019.10.30 DayOne Expert Event patient centricity
2019.10.30 DayOne Expert Event patient centricity2019.10.30 DayOne Expert Event patient centricity
2019.10.30 DayOne Expert Event patient centricity
 
DayOne Accelerator 2019/20 shortlisted projects
DayOne Accelerator 2019/20 shortlisted projectsDayOne Accelerator 2019/20 shortlisted projects
DayOne Accelerator 2019/20 shortlisted projects
 

Recently uploaded

New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
AkankshaAshtankar
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
NEHA GUPTA
 
Effective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptxEffective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptx
SwisschemDerma
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
SURGICAL ANATOMY OF THE RETROPERITONEUM, ADRENALS, KIDNEYS AND URETERS.pptx
SURGICAL ANATOMY OF THE RETROPERITONEUM, ADRENALS, KIDNEYS AND URETERS.pptxSURGICAL ANATOMY OF THE RETROPERITONEUM, ADRENALS, KIDNEYS AND URETERS.pptx
SURGICAL ANATOMY OF THE RETROPERITONEUM, ADRENALS, KIDNEYS AND URETERS.pptx
Bright Chipili
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
Suraj Goswami
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Yodley Lifesciences
 
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
ShashankRoodkee
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Colonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implicationsColonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implications
Dr Maria Tamanna
 

Recently uploaded (20)

New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAdv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
 
Effective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptxEffective-Soaps-for-Fungal-Skin-Infections.pptx
Effective-Soaps-for-Fungal-Skin-Infections.pptx
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
SURGICAL ANATOMY OF THE RETROPERITONEUM, ADRENALS, KIDNEYS AND URETERS.pptx
SURGICAL ANATOMY OF THE RETROPERITONEUM, ADRENALS, KIDNEYS AND URETERS.pptxSURGICAL ANATOMY OF THE RETROPERITONEUM, ADRENALS, KIDNEYS AND URETERS.pptx
SURGICAL ANATOMY OF THE RETROPERITONEUM, ADRENALS, KIDNEYS AND URETERS.pptx
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
 
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Colonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implicationsColonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implications
 

Funding of early stage companies

  • 1. Marsa Corporate Finance GmbH, Basel Switzerland Financing of Early-stage Companies Strictly private andconfidential April 2019 An Overview of Funding Facilities to baselarea.swiss DayOne Accelerator, 30.04.2019
  • 2. 1 Introduction and Investment Thoughts 2 Development Stage of Companies 3 Life Cycle 4 Financing Means 4.1 Equity 4.2 Equity Investor Types 4.3 Loans 4.4 Loan Characteristics 4.5 Non-dilutive Funding 5 Investment Size and Expected Returns - IRR 6 Business Case Presentation 7 Contact Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 2 Contents
  • 3. Introduction to Fund Raising for Early-stage Companies Valuation of early-stage companies Marsa Corporate Finance GmbH April 2019 3 1 Introduction and Investment Thoughts
  • 4. Your Fund Raising Strategy should based on important parameters, such as • which round of financing is it? • which development phases is your startup/project in? • which is the investment size? • which future funds will the company/project need and when? • which type of funds should be applied for (Equity, non-Equity)? • which types of investors are best to approach? • which is the company’s offer to investors? Introduction 1 Introduction & InvestmentThoughts Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 4
  • 5. Development stage of young companies 2 Early Stage Companies Role in theEconomy Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 5 Revenues Business/Product Idea No revenues, Operatinglosses Start-up companies No or small revenues, Increasing losses 2nd stage companies Growing revenues move towardsprofits Losses/earnings
  • 6. ~ 8-14 20 YEARS RESEARCH & DEVELOPMENT PHASE RETURN PHASE EXPIRY REGISTRATION PHASEIII PHASEII PHASEI PRE-CLINICALSAFETY DOSE EFFICACY / APPROVAL “STAR” “CASH COW” “DOG”~10 % 10 -45% 40 - 65% ~80% BREAKEVE N ß RISK-ADJUSTED DISCOUNTED CASH FLOW à Chance of SUCCESS <5% ANIMALS ~10s ~ 100s ~ 100s – 1,000s PTS COSTS SALESp<0.05 P/E >20x P/E ~10-15x P/E > 6-10x “MATURE” P/E ~ 15x 0 LIFE CYCLE BIOTECHNOLOGY COMPANIES 00 Life cycle of young companies, e.g. Pharmaceutical 2 Early Stage Companies Role in theEconomy Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 6 Valuation Methods DCF, rNPV Multiples, Peer groups, other
  • 7. Paid in at inception of the startup company by the founders: ◦ In GmbH CHF 20k ◦ In AG CHF 100k ◦ From founder shareholders ◦ Possible is some in-kind or partial pay-in (e.g. 50% = «Teil-Liberierung») ◦ Rapidly consumed Equity - Initial Share Capital Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 7 4 Financing Means
  • 8. Early Stage: (50k – 500k) • FFF – pure money • Seed Investors, some early-stage VC • Business Angels – often with some «soft money» as contacts and support Expansion Phase • Venture Capital Investors Late Stage • Venture Capital Investors • Private Equity Investors Other types • Crowd Funding • Corporate Ventures • Family Offices Equity – Investors Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 8 4 Financing Means
  • 9. Loans may come in various constructs with rather different implications and at different stages • Straight loans e.g. from banks or private investors (rather in a later stage) • Convertible loans (rather early, e.g. if no meaningful valuation is possible) • Option Debentures (rather unusual in early stage startups) • Warrants • .... Loans Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 9 4 Financing Means
  • 10. Straight loans • Interest baring or without interest • Liabilities in balance sheet • Subordination possible to cure Convertible loans • Compare to straight loans, however can be converted into equity • Subordination possible to cure • «switch side» on balance sheet in case of over-indebtedness • Conversion triggers are important • Who holds right to convert and when? Loan Characteristics Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 10 4 Financing Means
  • 11. Option debentures • Special form of convertible, not very common • type of debt instrument unsecured by collateral, hence rely on the creditworthiness and reputation of the issuer for support. • may pay periodic interest payments Warrants • do not represent actual ownership in the stock • holder has the right to buy stock from the company at a specified price within a designated time period • Dilution,because the exercise of a warrant will increase a company's outstanding shares Loan Characteristics Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 11 4 Financing Means
  • 12. • Governmental or supra-national grants EU, Innosuisse, • Foundations offer project funding or individuals’ support Gebert Ruef, Hasler, etc. .... • Donations • Patient organisations • Refunds or reductions of Development Cost (EMA), Orphan, etc., ..... Non-dilutive Funding Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 12 4 Financing Means
  • 13. Typical Investment Size – IRR Expectations 5 Investment Size and Expected Returns - IRR Investor Total Investment Size IRR Business Angel CHF 10k + n.a. FFF n.a. n.a. Early-stage VC CHF 0.5 -5.0m > 10% Late-stage VC CHF 5m + > 10% Private Equity CHF xxm > 12-16% Non-dilutive variable n.a. The internal rate of return (IRR) is the discount rate providing a net value of zero for a future series of cash flows. IRR and net present value (NPV) are used when selecting investments based on their returns. The main difference between IRR and NPV is that NPV is an actual amount while the IRR is the interest yield as a percentage expected from an investment.
  • 14. Investors Expectations – ROI - Return Return in investment is the difference between Profits minus Cost in relation to Cost or: Example: Investor puts 50 € and yields at end of investment 70 €; Return = 40 %: Earnings – Cost Earnings Return = ---------------------- = -------------- -1 Cost Cost Profit Return = -------------------------- Invested Capital 70 – 50 20 Return = -------------- = ------- = 40% 50 50 5 Investment Size and Expected Returns - IRR
  • 15. IRR Calculating IRR A company is deciding whether to purchase new equipment that costs $500,000. Life of the new asset to be 4 years generate an additional $160,000 of annual profits. In the 5. year, the company plans to sell the equipment for its salvage value of $50,000. Meanwhile, another similar investment option can generate a 10% return. This is higher than the company’s current hurdle rate of 8%. The goal is to make sure the company is making better use of its cash. To make a decision, the IRR for investing in the new equipment is calculated below. IRR of 13%, using the Excel function, =IRR(). From a financial standpoint, the company should make the purchase, because the IRR is both greater than the hurdle rate and the IRR for the alternative investment. 5 Investment Size and Expected Returns - IRR Find IRR and NPV functions as preset functions in MS Excel
  • 16. Business Case Presentation Fund Raising Document Set consists of • Pitch Deck • Business Plan incl. Financial Plan (3+ years) PnL, CF, BS • IP Situtation and Strategy • Use of Funds – incl. Scenarios • Next Financing Needs (Timing, Size) • Supplement Documents Important Aspects • Consistency of all documents and messages • Be reliable and deliver • Communicate important events in timely manner – no surprises 6 Investment Size and Expected Returns - IRR
  • 17. Thank you - Your contact at Marsa Corporate Finance GmbH 7 Contact Andreas J. Schulze, CEO Marsa Corporate Finance GmbH 4010 Basel www.marsaco.com +41 76 341 18 76 andreas.schulze@marsaco.com Financing of early-stage companies Marsa Corporate Finance GmbH April 2019 17